Background: Recently, microRNAs (miRNAs) have attracted much attention as novel players in the pathogenesis of mesial temporal lobe epilepsy (MTLE) in mature and developing brains. This study aimed to investigate the expression dynamics of miR-9, miR-138, miR-181a, miR-221, and miR-222 in the hippocampus of an immature rat model during the three stages of MTLE development and in children with MTLE. Methodology: qPCR was used to measure expression levels during the three stages of MTLE development (2 h, 3, and 8 weeks after induction of lithium-pilocarpine status epilepticus, representing the acute, latent, and chronic stages, respectively. Expression levels were also measured in hippocampi obtained from children with MTLE and normal controls. Results: In the rat model, miR-9 was significantly upregulated during the acute and chronic stages relative to controls, but not during the latent stage. MiR-138, miR-221 and miR-222 were all downregulated during all three stages of MTLE development. MiR-181a was downregulated during the acute stage, upregulated during the chronic stage, and unaltered during the latent stage. In children, miR-9 and miR-181a were upregulated, while miR-138, miR-221, and miR-222 were downregulated. Conclusion: Modulation of these miRNAs may be a new strategy in designing antiepileptic and anticonvulsant therapies for the developing brain.
Introduction
Epilepsy is a common disorder affecting up to 1% of the population, with one-third of patients having pharmacoresistant seizures. Mesial temporal lobe epilepsy (MTLE) is a common, chronic type of epilepsy, characterized by recurrent spontaneous seizures originating in brain structures such as the hippocampus [1] . Although temporal lobe epilepsy (TLE) is often diagnosed in adolescence or adulthood, the processes leading to epilepsy may begin earlier, possibly during childhood. Molecular changes contributing to the development of epilepsy are under intense study in the hopes of better understanding the pathogenesis and identifying targets for therapies aimed at treating and even preventing epilepsy.
MicroRNAs (miRNAs) are a class of small, noncoding RNAs of ~21-23 nucleotides that regulate gene expression at the posttranscriptional level [2] . They are believed to fine-tune many biological processes, such as developmental timing and tissue differentiation. Moreover, miRNA deregulation has been implicated in various diseases including pediatric chronic, central nervous system (CNS), and cardiovascular diseases, reviewed in [3] [4] [5] .
A number of miRNAs have been identified as being brain-specific, or at least highly enriched in brain relative to other tissues. Initially identified as a brain specific miRNA, miR-9 plays a major role in brain development and is expressed specifically in neurogenic regions of the brain during neural development [6] . It has been implicated in several aspects of neuronal development and function [7] , and has also recently been shown to be a pro-inflammatory miRNA and involved in modulating the nuclear factor Kappa-B (NF-κB)-dependent inflammatory response [8] .
MiR-138 is highly enriched in brain, is localized within dendrites, negatively regulates the size of dendritic spines in rat hippocampal neurons, and is involved in the development of several organs [9, 10] . MiR-138 also modulates DNA damage and is an important regulator of the genomic stability [11] . Very recently, downregulation of miR-138 has been found to contribute to the constitutive activation of NF-κB [12] .
MiR-181a is involved in the development and differentiation of lymphoid and myeloid cells [13] , and plays a very important role in the host inflammatory response [14] . In the CNS, it influences the outcome of cerebral ischemia [15] .
MiR-221 and miR-222 are two highly homologous miRNAs, dysregulation of which have been described recently in several types of human tumors. These two miRNAs are considered to be hippocampal enriched [16] .
In vitro experiments have revealed that miR-221 and miR-222 target the 3´UTR of intercellular adhesion molecule 1 (ICAM1) [17] , which in turn mediates interactions with immune cells to influence the inflammatory process [18] .
Because of their known enriched expressions in the brain and their roles in brain development and the CNS, we hypothesized that miR-9, miR-138, miR-181a, miR-221, and miR-222 expression levels are associated with the development of MTLE. In this study, we tested for the first time whether their expression levels are altered during the three stages of MTLE development in an immature rat model, and in the brains of children with MTLE.
Experimental procedures

Experimental animals
We started our experiment with 55 immature [19] .
Only animals classified higher than stage 3 were used in this study. SE was defined as seizure-like activity lasting at least 30 minutes.
Intra-peritoneal pilocarpine administration Clinical information on children with MTLE and controls has been described previously [20] .
Rat tissue preparation for RNA isolation
The immature rats were sacrificed under deep anesthesia by an intraperitoneal injection of chloral hydrate (10%, 5 ml/kg) at 2 hours and at 3 and 8 weeks after pilocarpine-induced SE or saline administration. After decapitation, the hippocampus was quickly removed using Assessment of miRNAs' (9, 138, 181a, 221, and 222) expression levels by qPCR in the hippocampi of immature rats and children with MTLE cDNA synthesis was performed using the One
Step PrimeScript® miRNA cDNA Synthesis Kit 
Statistical analysis
All of the data are expressed as means ± standard deviation. A Student's t test was performed to determine significant differences between two groups. One-way analysis of variance was utilized to determine significant differences among multiple groups. The value of p<0.05 was considered to be statistically significant. In human tissues, miR-9, miR-138, miR181a, miR-221 and miR-222 expressions were normalized to that of the human U6B small nuclear RNA gene (rnu6b) (p<0.05).
Results
Dynamics
Discussion
MTLE is the most prevalent form of refractory symptomatic epilepsy [21] . Despite the high prevalence and extensive research, mechanisms of the cause and progression of epilepsy are still unknown [22] . It has been well established that early in life the brain is more susceptible to seizures. About 50% of cases the onset of epilepsy occurs in childhood and in elderly, with half of those being under one year of age [23] . Molecular changes triggered by an epileptogenic insult can continue to progress after the epilepsy diagnosis, even though they might qualitatively and quantitatively differ at various phases of the epileptic process [24, 25] .
Interestingly, it is now clear that miRNAs regulate many aspects of the pathogenic mechanisms underlying MTLE development.
Selective reduction in Dicer levels in tissue from TLE patients with severe hippocampal sclerosis (HS), suggested that Dicer loss may contribute to the pathogenesis of TLE-HS [26] . MiR-184 has been identified as a seizure-regulated miRNA and its inhibition increases neuronal death after seizures [27] . MiR-34a is upregulated and contributed in seizure-induced neuronal death [28] . Kan et al. (2012) profiled the miRNAs changes in human TLE [17] . Our previous experiments supported the role of inflammation-related miRNAs (miR-146a, -155, -21, and -132) and brain-specific miRNAs (miR-124 and -134) in the pathogenesis of MTLE in immature rat models and children [20, 29, 30] .
On the therapeutic level, miR-134a silencing produces neuroprotective and prolonged seizure-suppressive effects [31] , while targeting miR-132 reduces seizure-induced neuronal death and protects the hippocampus [32] .
In this experiment, we assessed for the first time the dynamics of miR-9, miR-138, miR181a, miR-221, and miR-222 expression during the three stages of MTLE development in PN25 immature rats, which nearly equal those of a human infant, and then tested them for differential expression in children with MTLE relative to controls.
Our results revealed an upregulation of brain-specific miR-9 in the seizure-related acute and chronic stages, but not during the seizurefree latent stage; this pattern of expression was the same for brain-specific miRNAs miR-124 and miR-134 in the same animal model [30] .
MiR-9 was previously found to be upregulated in response to epileptic preconditioning [27] and in the chronic stage of MTLE [33] . Induction and involvement of miR-9 in the fine tuning of NF-κB-dependent inflammatory response In conclusion, our study shows that miR- 
